WebMD explains the causes, symptoms, and treatment of Duchenne muscular dystrophy, a rare muscle disease that mainly affects mainly boys in early childhood.

The Food and Drug Administration approved the first gene therapy for Duchenne muscular dystrophy, but limited access to those ages four and five. Accessibility links Skip to main content ...

Duchenne muscular dystrophy causes progressive muscle weakness that can rob kids of their ability to walk by the time they’re teenagers, and many don’t live well into their 30s. It affects an ...

The FDA has approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children 4-5 years of age. Get the details on how Elevidys could help pediatric patients.

The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...